Serum Levels of Insulin-like Growth Factor-I. Pentosidine and Adinopectin as Markers for Assessing Bone Condition in Women With Type 2 Diabetes

Ippei Kanazawa and Toru Yamaguchi (Editors)
Shimane University, Japan

Series: Neurology – Laboratory and Clinical Research Developments
BISAC: MED056000

Clear

$0.00

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Although bone mineral density (BMD) is considered as a gold standard for evaluating fracture risk in non-diabetic osteoporosis, accumulative evidence shows that patients with type 2 diabetes have high fracture rate in spite of the absence of BMD reduction, indicating that BMD is not sensitive enough to assess the risk of osteoporotic fractures in them. In addition, hyperglycemia itself is not associated with BMD or fracture risk, either. Therefore, the etiology of diabetes-related bone fragility and its diagnostic markers replacing BMD need to be explored. This new book discusses how serum adiponectin level was associated with serum osteocalcin in patients with type 2 diabetes in clinical studies (Imprint: Nova Biomedical)

Abstract

Introduction

Advanced Glycation End Products (AGEs) and Bone Metabolism in Type 2 Diabetes

Insulin-Like Growth Factor-I (IGF-I) and Bone Metabolism in Type 2 Diabetes

Adiponectin and Bone Metabolism in Type 2 Diabetes

Relationships between Bone and Glucose Metabolism through the Action of Osteocalcin and Adiponectin

Conclusion

References

Index

You have not viewed any product yet.